EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

These naturally occurring hormones play crucial roles in regulating insulin ... marked doses on the pens (0.25, 0.5, 1.0 and ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes. Following an update from the company (Novo Nordisk), ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations ... marketed as Ozempic, are non-insulin GLP-1 drugs. That’s shorthand for ...

It also included the provision of needles and travel wallets free of charge. For another chain Novo Nordisk provided “financial support for the development of the Medicated Weight Loss programme, ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

And Novo Nordisk is asking the U.S. Food and Drug Administration (FDA) to bar compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight ...